Group 1 - The company, Zhongji Changshou Science (00767), has signed a non-binding memorandum of understanding to acquire 100% equity of the target company, Comprehensive Cell Bank Limited, from China International Orthopedic Medical Group Limited [1] - The target company specializes in cell therapy, cell drug research and development, and health longevity management services, holding the Comprehensive Cell Bank [1] Group 2 - Comprehensive Cell Bank is the world's largest international autologous immune cell bank and is recognized for meeting various international standards, including FDA, AABB, and PIC/S cGMP [2] - It is the only clinical cell bank in Asia registered with the FDA for both immune cells and stem cells, ensuring compliance with international standards for cell management [2] Group 3 - The Comprehensive Cell Bank began operations on November 17, 2018, and possesses patented technologies in cancer early screening, NK cells, stem cells, and cartilage cells, along with 22 advanced medical testing platforms [3] - The company can provide services to 300,000 people globally, with potential revenue exceeding HKD 30 billion from immune cell storage, cancer early screening, longevity medical testing, and related cell therapies [3]

Group 1 - The company, Zhongji Changshou Science (00767), has signed a non-binding memorandum of understanding to acquire 100% equity of the target company, Comprehensive Cell Bank Limited, from China International Orthopedic Medical Group Limited [1] - The target company specializes in cell therapy, cell drug research and development, and health longevity management services, holding the Comprehensive Cell Bank [1] Group 2 - Comprehensive Cell Bank is the largest international autologous immune cell bank in the world and is recognized for meeting various international standards, including FDA, AABB, and PIC/S cGMP [2] - The bank addresses the global challenge of insufficient international standard cell quantities and ensures safe and effective applications, positioning itself as a leading international cell transformation application platform [2] Group 3 - Since its operation began on November 17, 2018, the Comprehensive Cell Bank has developed patented technologies in cancer early screening, NK cells, stem cells, and chondrocytes, and operates 22 advanced medical testing platforms [3] - The bank can provide services to 300,000 people globally, focusing on immune cell storage, cancer early screening, longevity medical testing, and cell therapy research and development, with potential revenue exceeding HKD 30 billion [3]

Group 1 - The company, Zhongji Changshou Science (00767.HK), has signed a non-binding memorandum of understanding to acquire 100% equity of the target company, Comprehensive Cell Bank Limited, from China International Orthopedic Medical Group Limited [1] - The target company specializes in cell therapy, cell drug research and development, and health longevity management services, holding the largest international autologous immune cell bank in the world [1][2] - Comprehensive Cell Bank is recognized as the only FDA, AABB, PIC/S cGMP, ISBER-IRL, FACT, CAP, and ISBT 128 compliant international clinical cell bank, addressing the global shortage of standard cells and ensuring safe and effective applications [1][2] Group 2 - The Comprehensive Cell Bank is the only FDA-registered immune cell and stem cell bank in Asia, meeting international standards for cell management and storage [2] - The facility, located in Hong Kong, has been operational since November 17, 2018, and possesses patented technologies for cancer early screening, NK cells, stem cells, and chondrocytes, along with 22 advanced medical testing platforms [2] - The target company aims to provide services to over 300,000 individuals globally, with potential revenue exceeding HKD 30 billion from its offerings in immune cell storage, cancer early screening, longevity medical testing, and related cell therapies [2]

Core Viewpoint - Zhongji Changshou Science (00767) has entered into a memorandum of cooperation with Haoshiduo (Shenzhen) Biotechnology Co., Ltd. to collaborate on longevity detection and management services, aiming to provide longevity-related products and health consultation services in the health industry [1][2] Group 1 - The cooperation will involve Zhongji Changshou's subsidiary, Hongfeng Development, providing product services and management system support, while Haoshiduo will supply domestic customer resources and market sales channels [1] - Haoshiduo is an innovative biotechnology company engaged in health, biotechnology research and development, and artificial intelligence application software development, with strong customer base and market expansion capabilities [1] - The board believes that the health and longevity science market has broad prospects, as wealthy customers globally are increasingly willing to invest in longevity science applications to enhance their overall health and immune status [1] Group 2 - The memorandum aligns with the group's strategy for developing longevity science business and is expected to benefit future business growth [2] - The board is confident that the cooperation will enhance the group's layout in the longevity science diagnostics and medical services sector, opening new revenue sources in longevity science [2] - The aim is to achieve more stable and sustainable revenue growth for the group in the long term [2]

Core Viewpoint - Zhongji Longevity Science (00767) has signed a memorandum of cooperation with Haoshiduo (Shenzhen) Biotechnology Co., Ltd. to collaborate on longevity detection and management services, aiming to provide longevity-related health products and services [1][2] Group 1: Cooperation Details - The cooperation involves Zhongji's subsidiary, Hongfeng Development, providing product services and management system support, while Haoshiduo will supply domestic customer resources and market sales channels [1] - Haoshiduo is an innovative biotechnology company engaged in health, biotechnology research and development, and AI application software development, with strong market capabilities and brand promotion [1] Group 2: Market Outlook - The board believes the health longevity science market has significant potential, as affluent customers are increasingly willing to invest in longevity applications to enhance their overall health and immune status [1] - The memorandum aligns with the group's longevity science business development strategy, which is expected to enhance the company's positioning in the longevity science diagnostics and medical services sector, creating new revenue streams for stable and sustainable growth [2]

Group 1 - The company, Zhongji Changshou Science, has signed a memorandum of cooperation with Haoshiduo Biotechnology to collaborate on longevity detection and management services [1] - The partnership aims to provide longevity biological products, medical testing, health consulting services, and management solutions within the health industry [1] - The company operates through its subsidiary, Hongfeng Development, which focuses on longevity science research, medical testing, biological products, and management [1] Group 2 - The board believes that the health and longevity science market has significant potential, as affluent customers are increasingly willing to invest in longevity applications to enhance their overall health and immune systems [2] - The memorandum aligns with the company's strategic development plan in the longevity science sector, which is expected to benefit future business growth [2] - The collaboration is anticipated to enhance the company's positioning in the longevity science diagnostics and medical services field, creating new revenue streams for long-term stable growth [2]